A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

Polo-like kinase 1 (Plk1) has an important role in mitosis. Volasertib (BI 6727), a potent and selective cell cycle kinase inhibitor, induces mitotic arrest and apoptosis by targeting Plk; this phase I study sought to determine its maximum tolerated dose (MTD) in Asian patients with advanced solid t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: C-C. Lin, Wu‐Chou Su, C-J. Yen, Chih‐Hung Hsu, W-P Su, Kun‐Huei Yeh, Yen‐Shen Lu, Ann‐Lii Cheng, Deng-Gao Huang, Holger Fritsch, Florian Voß, Tillmann Taube, James Chih‐Hsin Yang
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Acesso em linha:https://doi.org/10.1038/bjc.2014.195
https://www.nature.com/articles/bjc2014195.pdf
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

https://doi.org/10.1038/bjc.2014.195
https://www.nature.com/articles/bjc2014195.pdf

Registros relacionados